Accessibility Menu
Inogen logo

Inogen(NASDAQ) INGN

Current Price$6.41
Market Cap$176.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-57%
5 Year-91%
1 Year+3%
1 Month+1%
Inogen last closing stock price
MetricPriceDate
Last closeUSD 6.512026-07-22
Inogen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.56%USD 6.412026-07-15
1 month+1.24%USD 6.432026-06-22
3 month-6.87%USD 6.992026-04-23
Year to date-3.12%USD 6.722025-12-31
1 year+2.68%USD 6.342025-07-22
3 year-24.13%USD 8.582023-07-21
5 year-90.92%USD 71.712021-07-23
Since inception-57.03%USD 15.152014-02-14

Inogen Financials at a Glance

Market Cap

$176.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$351.50M

Net Income (TTM)

-$24.90M

EPS (TTM)

-$0.92

P/E Ratio

-7.10

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$6.41

Volume

3,058

Open

$6.52

Previous Close

$6.51

Daily Range

$6.37 - $6.54

52-Week Range

$5.34 - $9.13

Estimated Earnings Date

Aug 6, 2026

INGN: Motley Fool Moneyball Superscore

53

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inogen

Inogen, Inc. is a leading medical technology company specializing in portable oxygen concentrators (POCs) for patients with chronic respiratory conditions. By concentrating ambient air to deliver supplemental oxygen, Inogen’s products allow for increased mobility and independence, crucial for those in need of long-term oxygen therapy. The company operates globally, providing innovative respiratory solutions across various markets, with a dedicated commitment to enhancing patient quality of life.

Products and Services

Inogen One: Portable oxygen concentrators featuring the latest Intelligent Delivery Technology.

Inogen Rove: Lightweight systems designed for mobility and ease of use.

Simeox: An airway clearance device for treating bronchiectasis and other conditions.

Inogen At Home: A stationary oxygen concentrator for continuous oxygen delivery.

What Makes Inogen, Inc. Special

Inogen's innovative product design and robust direct-to-consumer sales model distinguish it within the portable oxygen concentrator market. This approach fosters stronger customer relationships, allowing for valuable feedback and continuous improvement. The company's commitment to customer-centric technology and comprehensive support services enhances mobility and independence for oxygen therapy users.

Five Things You Need to Know

Inogen's POCs improve patient mobility, reducing reliance on stationary devices and oxygen tanks.

The company pioneered the direct-to-consumer sales model in the oxygen therapy sector.

Recent acquisition of Physio-Assist expands Inogen's reach into the bronchiectasis market.

The executive team prioritizes operational excellence and strategic market expansion.

Inogen invests heavily in R&D to lead the development of next-generation respiratory solutions.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Employees

753

CEO

Kevin R. M. Smith, MBA

Headquarters

Beverly, MA 93117, US

INGN Financials

Key Financial Metrics (TTM)

Gross Margin

48.73%

Operating Margin

-8.81%

Net Income Margin

-7.08%

Return on Equity

-12.90%

Return on Capital

-14.40%

Return on Assets

-8.71%

Earnings Yield

-14.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$176.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

27.07M

Volume

3.06K

Avg. Volume

313.68K

Financials (TTM)

Gross Profit

$171.29M

Operating Income

-$30.97M

EBITDA

-$5.23M

Operating Cash Flow

-$1.11M

Capital Expenditure

-$9.13M

Free Cash Flow

-$10.24M

Cash & ST Invst.

$111.47M

Total Debt

$16.94M

Inogen Performance Analysis

Inogen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 377,241,0005.4%
20232023-12-31USD 315,660,000-16.3%
20242024-12-31USD 335,705,0006.4%
20252025-12-31USD 348,668,0003.9%
Inogen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3012.1%
Q32025-09-300.1%
Q42025-12-31-11.5%
Q12026-03-314.1%
Inogen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.671201.8%
20232023-12-31USD -4.4220.6%
20242024-12-31USD -1.52-65.7%
20252025-12-31USD -0.86-43.6%
Inogen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3040.0%
Q32025-09-30-33.3%
Q42025-12-31-30.0%
Q12026-03-31-15.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$85.11M

+3.4%

Gross Profit

$41.77M

+14.8%

Gross Margin

49.08%

N/A

Market Cap

$176.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$234.07K

N/A

Employees

753

N/A

Net Income

-$8.32M

-34.8%

EBITDA

-$3.59M

-232.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$111.47M

-6.2%

Total Debt

$16.94M

-11.9%

Accounts Receivable

$41.87M

+14.3%

Inventory

$24.99M

-4.9%

Long Term Debt

$13.44M

-17.4%

Short Term Debt

$3.49M

+18.6%

Return on Assets

-8.71%

N/A

Return on Invested Capital

-13.80%

N/A

Free Cash Flow

-$7.47M

+60.3%

Operating Cash Flow

-$6.69M

+60.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QTRXQuanterix Corporation
$3.87+0.78%
HCATHealth Catalyst, Inc.
$2.04-0.25%
EPRXEupraxia Pharmaceuticals Inc.
$6.35-1.09%
HSDTSolana Company
$1.72-0.87%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.88-0.28%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.16+0.05%
HBANHuntington Bancshares
$17.38-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$37.03+0.08%

Questions About INGN

What is the current price of Inogen?

Inogen is trading at $6.41 per share.

What is the 52-week range for Inogen?

Over the past 52 weeks, Inogen has traded between $5.34 and $9.13.

How much debt does Inogen have?

As of the most recent reporting period, Inogen reported total debt of $16.94M.

How much cash does Inogen have on hand?

Inogen reported $94.41M in cash and cash equivalents in its most recent financial results.

What is Inogen’s dividend yield?

Inogen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.